MiniMed Group (MMED) SEC filings document the regulatory record of a Nasdaq-listed diabetes technology company focused on insulin delivery systems, CGMs, sensors, algorithms, and app-connected diabetes management. MiniMed's filings include annual reports, quarterly reports, proxy statements, and Form 8-K material event reports.
For MMED, the most relevant filings often relate to medical device operations and newly public company governance. Annual reports and 10-Q filings can describe business structure, risk factors, capital structure, financial results, clinical and regulatory matters, and disclosures tied to MiniMed's separation from Medtronic. Form 8-K filings have covered financial results, board appointments, executive compensation plans, officer departures, cybersecurity-related disclosures, and other material events.
Proxy statements are useful for reviewing director elections, auditor ratification, advisory compensation votes, and governance matters. Form 4 insider transaction filings can show reported purchases, sales, or equity awards by directors and officers when such filings are submitted. 10-K and 10-Q reports are especially important for understanding how MiniMed reports its diabetes technology business after becoming a public company.
AI-powered summaries can translate dense filing language into plain-English explanations, while real-time EDGAR updates can surface new MMED filings as they are released. These summaries are most useful when reviewing long annual reports, quarterly updates, proxy statements, and insider transaction disclosures.
MiniMed Group, Inc. (MMED) is the issuer in a Schedule 13G reporting five entities’ beneficial ownership of its common stock: each lists 21,911,680 shares, or 7.8% of the class. The reporting persons are Capital Ventures International, Susquehanna Advisors Group, Inc., Susquehanna Fundamental Investments, LLC, Susquehanna Portfolio Strategies, LLC and Susquehanna Securities, LLC.
They state they may be deemed a group and report shared voting and dispositive power over 21,911,680 shares. Each reporting person disclaims beneficial ownership of shares directly owned by another reporting person. MiniMed’s Form 10-Q indicated 281,349,931 shares outstanding as of September 3, 2026.
Kevin E. Lofton reported acquisition or exercise transactions in this Form 4 filing. MiniMed Group, Inc. issued 836 common shares to director Kevin E. Lofton on October 15, 2026, in exchange for 182 Medtronic plc ordinary shares accepted in the completed exchange offer. The final exchange ratio was 4.5939 MiniMed common shares for each accepted Medtronic ordinary share. Lofton’s resulting MiniMed holdings were 40,409 shares, including shares to be issued in connection with vesting of one or more restricted stock units.
Ali Dianaty reported acquisition or exercise transactions in this Form 4 filing. MiniMed Group, Inc. (MMED) issued 11,108 shares of common stock to EVP Ch. Prod. & Tech Officer Ali Dianaty on October 15, 2026, in exchange for 2,418 Medtronic plc ordinary shares accepted in the completed exchange offer. The offer covered up to an aggregate of 252,813,348 newly issued shares, with a final exchange ratio of 4.5939 MiniMed shares per accepted Medtronic ordinary share. Dianaty’s reported direct holdings after the transaction were 326,266 shares, including shares to be issued in connection with vesting of one or more restricted stock units.
MiniMed Group, Inc. (MMED) reported that Gillian Chandrasena, SVP, Chief HR Officer, acquired 1,800 shares of common stock on October 15, 2026, when MiniMed issued shares upon completion of an exchange offer. Chandrasena received the shares in exchange for 392 Medtronic plc ordinary shares accepted in the offer, at a final exchange ratio of 4.5939 MiniMed shares for each Medtronic share. Her reported holdings after the transaction were 174,545 shares, including shares to be issued in connection with restricted stock unit vesting.
MiniMed Group, Inc. director Robert (Bob) Hopkins received a grant of 11,877 restricted stock units (RSUs) on October 15, 2026. The reported post-transaction amount is 11,877 shares, including common stock to be issued in connection with vesting of one or more RSUs.
MiniMed Group, Inc. director David J. Endicott received a grant of 3,374 restricted stock units under the 2026 MiniMed Group, Inc. Long Term Incentive Plan on October 15, 2026; the units vest on October 9, 2027. His reported post-transaction position was 15,169 shares, including common stock to be issued in connection with the vesting of one or more RSUs.
MiniMed Group, Inc. (MMED) director Amy Bricker received a grant of 11,877 restricted stock units (RSUs) under the 2026 MiniMed Group, Inc. Long Term Incentive Plan. The RSUs vest on October 9, 2027. The reported resulting position includes shares of common stock to be issued in connection with vesting.
MiniMed Group, Inc. was separated from Medtronic plc on October 15, 2026, through a split-off exchange offer. Medtronic exchanged MiniMed common stock representing approximately 90% of outstanding common stock for Medtronic ordinary shares held by Medtronic shareholders. Medtronic then ceased to own MiniMed common stock. The amended ownership report records 0 shares beneficially owned (0.0%) and zero sole or shared voting and dispositive power.
MiniMed Group, Inc. (MMED) reports that Medtronic plc, a 10% owner, disposed of 252,813,348 shares of MiniMed common stock in a completed exchange offer on October 15, 2026, in exchange for 55,032,401 ordinary shares of Medtronic. Medtronic owned no MiniMed common shares after the exchange.